Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

10.2%

12 terminated out of 118 trials

Success Rate

79.7%

-6.8% vs benchmark

Late-Stage Pipeline

3%

4 trials in Phase 3/4

Results Transparency

19%

9 of 47 completed with results

Key Signals

9 with results80% success12 terminated

Data Visualizations

Phase Distribution

98Total
Not Applicable (26)
Early P 1 (2)
P 1 (29)
P 2 (37)
P 3 (3)
P 4 (1)

Trial Status

Completed47
Recruiting28
Unknown15
Terminated12
Active Not Recruiting10
Suspended3

Trial Success Rate

79.7%

Benchmark: 86.5%

Based on 47 completed trials

Clinical Trials (118)

Showing 20 of 20 trials
NCT03127774Phase 2Active Not Recruiting

Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma

NCT07001748Phase 2Recruiting

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

NCT04034251Phase 2Terminated

Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

NCT04929015Not ApplicableSuspended

Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)

NCT03732768Phase 1CompletedPrimary

Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis

NCT04220827Phase 1Active Not Recruiting

Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer

NCT04847063Phase 1Recruiting

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

NCT04779554Phase 2RecruitingPrimary

Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC

NCT07493876Not ApplicableRecruitingPrimary

Enhanced Recovery After Surgery (ERAS) in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery With or Without HIPEC

NCT02758951Phase 2Active Not Recruiting

Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases

NCT07487168Phase 1Not Yet RecruitingPrimary

Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors

NCT07478107CompletedPrimary

Molecular Citology to Detect Free Cancer Cells in Peritoneal Fluid

NCT06144853Completed

The PIPAC-OPC7 Study: The Use of PET/CT Scans as a Method of Evaluation in Patients Treated With PIPAC, a Pilot Study.

NCT06504147Phase 2RecruitingPrimary

A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery

NCT07282834Phase 2Recruiting

Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)

NCT06511037Early Phase 1Recruiting

PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis

NCT05159050Phase 1TerminatedPrimary

Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis

NCT03252938Phase 1Active Not Recruiting

Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors

NCT06929013Not ApplicableRecruitingPrimary

Blood Clearance Kinetics of the Nucleosome and CTCF in Peritoneal Metastasis Colorectal Cancer.

NCT06623396Phase 1Recruiting

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

Scroll to load more

Research Network

Activity Timeline